3D Bioprinting of High-Grade Serous Ovarian Cancer Cells: Workflow for Gelatin-Based Bioink Formulation with Hyaluronic Acid and Printability Assessment
Randomized trial investigates bioprinting outcomes for high-grade serous ovarian cancer cells, suggesting bioink impacts cell viability and behavior.
Key Points
This research aims to develop a 3D bioprinting workflow for high-grade serous ovarian cancer cells and examine the influence of bioink formulation on cellular responses.
Developed a workflow for bioprinting with methacrylated gelatin and hybrid formulations
Optimized bioink for stable bioprinting and characterized rheological properties
Evaluated cellular responses including viability and marker expression after bioprinting.
Postprinting viability reached approximately 80–99% after 14 days, depending on hydrogel type and cell line
KURAMOCHI and SKOV3 cells showed higher viability in HAGel compared to OVCAR3 cells in GelMA
Scaffold composition significantly influenced cell responses and expression of hyaluronic-acid-associated markers.